These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25267496)

  • 1. Characteristic "pebbling" skin eruption as a presenting sign of Hunter syndrome.
    Noh TK; Han JS; Won CH; Chang S; Choi JH; Moon KC; Lee MW; Yang JH; Soung JH
    Int J Dermatol; 2014 Dec; 53(12):e594-6. PubMed ID: 25267496
    [No Abstract]   [Full Text] [Related]  

  • 2. Hunter syndrome: resolution of extensive typical skin lesions after 9 months of enzyme replacement therapy with idursulfase.
    Marín LL; Gutiérrez-Solana LG; Fernández AT
    Pediatr Dermatol; 2012; 29(3):369-70. PubMed ID: 21995841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical practice guideline for the management of Hunter syndrome. Hunter España working group].
    Guillén-Navarro E; Blasco AJ; Gutierrez-Solana LG; Couce ML; Cancho-Candela R; Lázaro P;
    Med Clin (Barc); 2013 Nov; 141(10):453.e1-13. PubMed ID: 24060500
    [No Abstract]   [Full Text] [Related]  

  • 5. [Early response to idursulfase in a 31-year old male patient with Hunter syndrome].
    Pérez-Calvo J; Bergua Sanclemente I; López Moreno MJ; Torralba Cabeza MÁ; Amores Arriaga B
    Rev Clin Esp; 2011; 211(7):e42-5. PubMed ID: 21524741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
    Serrano CD; Gomez JF
    J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
    [No Abstract]   [Full Text] [Related]  

  • 7. [Early enzyme replacement therapy - hope for patients with mucopolysaccharidosis Type II].
    Orchel-Szastak K; Ptak K; Hrnciar K; Pilch B; Kania U; Bik-Multanowski M
    Pediatr Endocrinol Diabetes Metab; 2017; 23(2):111-116. PubMed ID: 29073295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hunter disease before and during enzyme replacement therapy.
    Hoffmann B; Schulze-Frenking G; Al-Sawaf S; Beck M; Mayatepek E
    Pediatr Neurol; 2011 Sep; 45(3):181-4. PubMed ID: 21824567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parental experience of enzyme replacement therapy for Hunter syndrome.
    Buraczewska M; O'Leary D; Walsh O; Monavari A; Crushell E
    Ir Med J; 2013 Apr; 106(4):120-2. PubMed ID: 23691848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucopolysaccharidosis type II, Hunter's syndrome.
    Tylki-Szymańska A
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.
    Wraith JE
    Acta Paediatr; 2008 Apr; 97(457):76-8. PubMed ID: 18339193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idursulfatase therapy in mucopolysaccharidosis type II: after 2.5 years of treatment--no benefit for older patients with multisystem involvement.
    Gucev ZS; Tasic V
    Pediatr Neurol; 2012 Mar; 46(3):199-200; author reply 200. PubMed ID: 22353301
    [No Abstract]   [Full Text] [Related]  

  • 15. First treatment for Hunter syndrome.
    FDA Consum; 2006; 40(6):5. PubMed ID: 17333554
    [No Abstract]   [Full Text] [Related]  

  • 16. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hunter syndrome follow-up after 1 year of enzyme-replacement therapy.
    Puiu M; Chirita-Emandi A; Dumitriu S; Arghirescu S
    BMJ Case Rep; 2013 Jan; 2013():. PubMed ID: 23307460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
    Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
    Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin eruption as the presenting sign of Hunter syndrome IIB.
    Demitsu T; Kakurai M; Okubo Y; Shibayama C; Kikuchi Y; Mori Y; Sukegawa K; Mizuguchi M
    Clin Exp Dermatol; 1999 May; 24(3):179-82. PubMed ID: 10354174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.